KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Multicenter randomized phase III study of high-dose therapy with autologous stem cell transplantation versus observation for patients with newly diagnosed peripheral T-cell lymphoma who achieved complete metabolic response after induction therapy (JCOG2210, TRANSFER study).

Ryosuke Kita, Kazuyuki Shimada, Ryunosuke Machida, Tetsuya Sekita, Keita Sasaki, Kenji Ishitsuka, Haruhiko Fukuda, Dai Maruyama, Wataru Munakata, Hirokazu Nagai, Japan Clinical Oncology Group Lymphoma Study Group

Jpn J Clin Oncol 55(2) 183-188

PMID39426803
PMCIDPMC12529067
DOI10.1093/jjco/hyae144
发表日期2024-10-19
摘要

摘要

Patients with peripheral T-cell lymphoma demonstrated a poor prognosis after obtaining a complete response with induction treatment compared to those with B-cell lymphoma. Once it relapsed, curative treatment is frequently limited to invasive treatments with significant treatment-related mortality, including allogeneic stem cell transplantation. The limitations of these treatment choices indicate the necessity for developing optimal consolidation therapies to prevent relapse. This multicenter randomized phase III trial aims to confirm the superiority of the high-dose therapy with autologous stem cell transplantation over observation alone in terms of progression-free survival for patients with newly diagnosed peripheral T-cell lymphoma who achieved complete metabolic response after induction therapy. A total of 140 patients from 52 hospitals will be enrolled in Japan over 5.5 years. This trial is registered in the Japan Registry of Clinical Trials as jRCTs031240169 (https://jrct.niph.go.jp/latest-detail/jRCTs031240169).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。